Biohaven Pharmaceutical (NYSE: BHVN) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Biohaven Pharmaceutical to similar companies based on the strength of its earnings, profitability, dividends, analyst recommendations, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for Biohaven Pharmaceutical and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven Pharmaceutical 0 0 6 0 3.00
Biohaven Pharmaceutical Competitors 573 2503 6734 134 2.65

Biohaven Pharmaceutical currently has a consensus target price of $38.00, indicating a potential upside of 26.37%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 16.71%. Given Biohaven Pharmaceutical’s stronger consensus rating and higher possible upside, equities analysts clearly believe Biohaven Pharmaceutical is more favorable than its peers.

Profitability

This table compares Biohaven Pharmaceutical and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biohaven Pharmaceutical N/A N/A N/A
Biohaven Pharmaceutical Competitors -4,595.20% -40.12% -43.59%

Earnings & Valuation

This table compares Biohaven Pharmaceutical and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Biohaven Pharmaceutical N/A -$63.67 million -5.76
Biohaven Pharmaceutical Competitors $217.40 million -$39.40 million -73.95

Biohaven Pharmaceutical’s peers have higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

47.8% of Biohaven Pharmaceutical shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Biohaven Pharmaceutical beats its peers on 7 of the 12 factors compared.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.